Please assess the completion status of the following clinical trial:

Trial Title: Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for Bone Marrow Biopsy:~1. Patients with Genitourinary (GU) Cancers and presence of existing patient derived xenograft or planned collection of tumor for PDX generation~2. Age ≥ 18 years.~3. Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.~4. Ability to undergo bone marrow biopsy~5. Laboratory requirements (Hematocrit 30%, Platelets 75,000 + 10\^6/l and WBC 4000 X 10\^6/l)~6. Karnofsky performance status \>70%~Exclusion Criteria for Bone Marrow Biopsy:~1. Participants with serious concurrent chronic or acute illness that would affect the safety of a bone marrow biopsy.~Inclusion Criteria for Tumor Biopsy~1. Patients with prostate cancer~   a. Biopsies in this study for diseases other than prostate cancer are not permitted.~2. Age ≥ 18 years.~3. Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.~4. Planned or willing to undergo a tumor biopsy. Biopsies may be for research or clinical purposes depending on the treating provider for men with prostate cancer. Biopsies in this study for diseases other than prostate cancer are not permitted~   1. For research only biopsies: At least one lymph node or bone metastatic amenable to a minimum risk biopsy in the opinion of the treating physician.~  2. For clinical purpose biopsies: There are no location or risk requirements.~5. Laboratory requirements (Hematocrit 30%, Platelets 75,000 X 10\^6/l and WBC 4000 X 10\^6/l)~6. Karnofsky performance status \>70%~Exclusion Criteria for Tumor Biopsy:~1. Participants with serious concurrent chronic or acute illness that would affect the safety of a tumor biopsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects from which PDXs have been generated. (Type: None): Subjects will be identified from which PDXs have been generated from an already approved IRB protocol.
- Subjects without an existing PDX (Type: None): Subjects with prostate cancer amenable to a tumor biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).